James Parkinson
As I write, it was 200 years ago that the London physician, James Parkinson, first published his observations on patients with what he called the 'shaking palsy'. 3, 4 He lived for another seven years, but if he could have boarded a time machine back in 1817 and travelled forward to 2017, I wonder what he would have thought about the progress in PD research that has been achieved over the last two centuries.
My guess is that, after adjusting to the notion of having a disease named after him, Parkinson would be very impressed with the degree of effort that has been put into characterising the disease in detail. However, he might be somewhat perplexed as to why a cure, or at least an effective and sustainable therapeutic strategy for the longterm management of PD, has yet to be found. Parkinson would also notice that many sufferers, despite modern treatment methods, still exhibit resting tremor and a range of related motor and non-motor symptoms, and that the disease remains recalcitrant to all efforts to reduce its rate of progression, despite many possibilities for intervention.
A Neuropathological Hallmark
If he were here now, Parkinson would no doubt be fascinated by the fact that the degeneration of dopamine neurons is especially pronounced in a very small and specific brain region (the substantia nigra). This degeneration affects up to several tens of thousands of neurons, where, for some largely obscure reason, they start to undergo selective programmed cell death (apoptosis), instead of continuing to perform normally by producing a chemical messenger (L-dopamine), which mediates signalling along projections innervating the basal ganglion, where motor function is controlled. Progressive neuronal loss is accompanied by the appearance of darkly-stained inclusions called Lewy bodies. 5, 6 Parkinson would now be able to appreciate how a drug called levodopa acts to alleviate PD symptoms, by enabling the passage of the missing dopamine, in a form in which it can traverse the blood-brain barrier and get into the brain. Likewise, he would now be able to understand why it is also possible to prescribe another type of drug classified as a dopamine agonist, which binds to different subtypes of the dopamine G-coupled receptor family 7 from those targeted by dopamine, permitting its use together with levodopa, without competition for the same binding sites.
Some Questions
Our time-traveller would probably be curious to know why, despite the subsequent discoveries of other types of drugs, levodopa is still the most effective means of managing the condition, some 60 years after its last clinical trials ended in success. 8 Given the enormous effort, financial support, and numbers of laboratory animals (many of them non-human primates) that have been expended, Parkinson would also wonder why the effectiveness of levodopa invariably wears off, even after it has been used for several years, and whether there could be better therapeutic options. 9 Parkinson would also soon appreciate that the lack of understanding of the specific mechanisms underlying PD is not for want of trying. In this regard, he would learn about the central role of a molecule called alpha-synuclein in neuronal cell toxic waste disposal (which accumulates in the Lewy bodies in the affected neurons), 5 and of the use of some eight different animal models that develop PD, either after being treated with a neurotoxin or due to the effects of a gene mutation. 10, 11 New Developments
The timing of Parkinson's hypothetical trip forward in time to 2017 would also have been very opportune, since some of the above questions are at last beginning to be addressed. For example, two pivotal studies have appeared over the past two years. One of these demonstrated that brain cells, called astrocytes, can be re-programmed to secrete L-dopamine. 12, 13 The resulting endogenous supply of the neurotransmitter might turn out to be moreeffective and longer-lasting than the one supplied as a drug. The second study relates to the discovery that neurons in the ganglion region -which, during levodopa treatment, have to continue being stimulated by L-dopamine -at some point undergo a process of DNA methylation. This could explain why they eventually stop responding even to fresh dopamine. 14 This phenomenon, initially observed in vitro, should, in principle, be reversible. 15 This might herald a seismic shift in drug therapy, prolonging its effects indefinitely.
Some More Questions
Having absorbed all of this information, Parkinson might well ask several additional questions, such as: a) How can the available animal models be suitable for studying a mainly chronic condition, when they themselves represent acute forms of the disease, and then in a different species?;
b) Why has so much effort been directed toward studying, at the expense of other potentially relevant molecules and processes, alphasynuclein, when it is involved in other neurodegenerative conditions?; c) Why has there been comparatively little interest in the possible involvement of several other affected brain areas (e.g. norepinephrine neurons of the locus coeruleus, cholinergic neurons of the nucleus basalis of Meynert, serotinergic neurons of the dorsal raphe, and neurons of the olfactory system, the pedunculopontine nucleus and the dorsal motor nucleus of the vagus)?; 10 d) Why do there appear to have been few in vitro mechanistic studies involving organotypic, differentiated neuronal tissue culture systems from subjects with and without PD?; and e) Is there more scope for other non-invasive patient studies?
Parkinson would hear that much of the existing information on the disease has been obtained from conducting animal experiments in which neurotoxins are used to reproduce many of the same neuropathological signs of the human conditions. However, these neuropathologies are induced under conditions of acute exposure, and progress at rates that are acute in timespan, rather than being of a chronic nature, as is the case with the most common human form of PD. What might be less obvious to Parkinson is that it has been alleged that such work has been hampered by fundamental differences in the onset, type and persistence of symptoms, and in physiology, and in the fact that nigral striatal degeneration can be sufficient to result in dyskinesia in humans, but not in non-human primates. 16, 15 
Deep Brain Stimulation
Our time-traveller would also soon become aware of an opportunity for further therapy, when all options involving conventional approaches have been exhausted. This process, known as deep brain stimulation (DBS), is enjoying what some have called a 'paradigm shift' in comparison to earlier experiences of its application to PD. 18 This renewed interest is a consequence of refinement of the techniques involved and improvements in therapeutic outcomes. Anne Beuter's paper in this issue of ATLA 19 describes DBS is detail, and reflects the current situation well. It is also highly relevant, because it suggests a way forward for improving DBS still further, by integrating information from patient studies to develop better, more-predictive computer simulations in a range of disciplines. Beuter, noting the pressure for more animal-based research into DBS, provides several examples, to which can be added a Windows-based software package StimExplorer. This software is designed to optimise parameters for use in the clinic, based on computer models of a quantitative description of the 3-D volume of tissue activated (VTA) by DBS as a function of the stimulation parameters and electrode location within the brain, together with 3-D virtual reality visualisation. 20 Parkinson's Verdict? I believe that James Parkinson, were he able to pass judgement on the progress made since 1817 in combating PD, would express surprise that the amount of research effort expended -particularly during the past half-century -has not resulted in a proportionate level of success in the development of methods for sustained, effective and reliable treatment. I also believe that he would call for more patient studies, in view of the difficulties inherent in developing animal models that can, firstly, recapitulate all of the subtle, non-motor (but nonetheless important) effects associated with PD, and, secondly, simulate the phenomenon of age-progression, in order to reflect its importance in the most common form of the human condition named after him.
He would surely also be more than supportive of the integrated use of in vitro organotypic tissue culture systems involving material from patient sources, and of computational methods. In this context, stem cell cultures from PD patients with a mutation in a parkin gene, which were stimulated to differentiate into mid-brain neuronal in vitro systems, were shown to exhibit electrical oscillations in response to L-dopamine via D1 receptor binding, while similar cultures from unaffected, non-mutant individuals were unresponsive. 21 This type of approach would also be compatible with the sentiments expressed about the importance of the Three Rs in biomedical research, in areas where there has traditionally been substantial use of laboratory animals, in yet another interesting publication in this issue of ATLA. 22 Let us hope that the next 50 years will be more usefully productive in the battle to defeat PD!
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